The Radiance 330® Proton Therapy System delivers vanguard proton therapy treatment with the precision of pencil-beam scanning and the power of integrated imaging.
Designed to increase accessibility, Radiance 330 is compact, modular, and scalable.
And with the lowest capital and operating costs of any proton therapy technology, Radiance 330 delivers the industry’s fastest return on investment.
Pencil-beam scanning with gating capability enables high treatment precision, improving long-term outcomes for patients and reducing side effects.1,2,3
Smallest synchrotron footprint in the market and a modular/flexible design that includes interchangeable sub-systems; can be installed in purpose-built or existing facilities.
Multiple imaging options including CBCT, 2-D X-ray with fluoroscopy, supporting image guided radiotherapy (IGRT).
Clinical treatment energy range of 70-250 MeV allowing for proton therapy treatment of any tumor site in the body.
Supports single- or multi-room facilities, and can be configured to allow for future expansion.
330 MeV capacity providing the accelerating capability for proton imaging of any anatomical area; dual-purpose beamline in development allowing for imaging and treatment with the same beam.
User-friendly and efficient interface system designed by proton clinical experts.
Utilizing a synchrotron does not require beam degrading, as with cyclotrons. Degrading causes secondary scatter radiation. Our synchrotron produces beam at the energy required, thus it produces far fewer neutrons. This means fewer neutrons to the patient, staff, ancillary equipment, and the building; less shielding required; no cooling-off period needed before entering the vault for routine maintenance.
1 W P Levin, H Kooy, J S Loeffler, T F DeLaney. “Proton Beam Therapy.” Br J Cancer. 2005 Oct 17; 93(8): 849–854. Published online 2005 Sep 27. doi: 10.1038/sj.bjc.6602754
2 University of Pennsylvania School of Medicine. “Studies point to clinical advantages of proton therapy: Studies demonstrated lower toxicities, positive survival outcomes for lung, pancreatic and spine cancers.” ScienceDaily. Published online 2015 Oct 19.
3 A R Smith. (2009), “Vision 20/20: Proton therapy.” Med. Phys., 36: 556–568. Published online 2009 Jan 26. doi:10.1118/1.3058485